Drug Profile
Respiratory syncytial virus-parainfluenza virus vaccine - Berna Biotech
Alternative Names: RSV-PIV vaccine - Berna BiotechLatest Information Update: 22 Jun 2011
Price :
$50
*
At a glance
- Originator Berna Biotech
- Developer Crucell
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parainfluenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 22 Jun 2011 Discontinued - Preclinical for Parainfluenza virus infections in Switzerland (unspecified route)
- 22 Jun 2011 Discontinued - Preclinical for Respiratory syncytial virus infections in Switzerland (unspecified route)
- 30 Dec 2002 Preclinical trials in Parainfluenza virus infections in Switzerland (unspecified route)